

177

10 01


二 木 研 輔
鈴 木 浩

Kiyoshi YASHIKAWA

インターロイキン-6 (IL-6) (1)(2)(3)(4)(5) は肝体内で R10

Ken-ko RUTATSUJI

Hiroshi OKAZAKI






FIG. 2. (A) N-terminus of the protein.

Fig. 5. Affinity-LIBC pattern of serum-free

serum-free culture media





FIG. 10. Construction of the recombinant plasmid vector.



2

1971年10月10日 中国科学院植物研究所



**

**

**

Anti-mIL-6R Control

**

% of Control

(pg/mouse/day) (ng/mouse/day) (adjuvant)

0 0 0

0 0 100

10 0 100

10 25 0

10

10 100 0

**

020

Ala Ile
GCC ATA



Ala
GCC TGA



Fig. 17. Insertion of stop codon into human gp130

cDNA

Fig. 18. Effect of oxidation of Met residues on bioactivity and binding to IL-6 receptor.




IL-6 (○), Met¹⁶²→Ala (●), Leu¹⁵⁹→Val



is produced in the culture medium of

RIUSA 社 1-1-1 東京都千代田区千代田 1-1-1





文 献

○ smIL-6R

今後、IL-6 阻害剤の研究においては
 培レト 17-6]、マブカニ培レトの薬理作用

Hirano, T., Yasukawa, K., Harada, H., Taga, T.

(1000)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

39) Nishimura, C., Hida, H., Masuda, S., Furutani

K. Itakura, Y. Kashi, M. Imai

40) Nishimura, C., Entatsugi, K., Yasukawa, K.